CTMX Q1 2017 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+424.2% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$9M-73.9% margin

Net Income

-$8M-70.9% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+85.8%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$178M

Total Liabilities

$104M

Stockholders' Equity

$74M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$2M	+424.2%
Gross Profit	$12M	$2M	+424.2%
Operating Income	-$9M	-$16M	+46.8%
Net Income	-$8M	-$16M	+48.5%